**Table S1.** Clinical and demographic characteristics of the patient populations.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | PLWHART | PLWHEC | PLWHVP | HC | P |
| N | 19 | 19 | 19 | 19 |  |
| Age, years; median (IQR) | 55 (45-61) | 46 (40-52) | 46 (32-53) | 49 (46-52) | 0.027\* |
| Gender, Female; n (%) | 6 (31.6) | 9 (47.4%) | 7 (36.8) | 8 (42.1) | ns\*\* |
| Duration of treatment in years; Median (IQR)# | 17 (7-20) | - | - | - | - |
| Duration of suppressive therapy in years; Median (IQR) # | 13 (7-17) | - | - | - | - |
| Nadir CD4+ T-cell, cells/µl; median (IQR) | 280 (130-420) | 530 (400-680) | 280 (180-350) | - | <0.001\* |
| CD4+ T-cell, cells/µl; median (IQR) # | 576 (520-700) | 880 (730-1050) | 300 (180-410) | - | <0.001\* |
| CD8+ T-cell, cells/µl; median (IQR) # | 580(450-730) | 780(525-890) | 740(530-910) | - | ns |
| CD4:CD8 Ratio;median (IQR) # | 1.09 (0.71-1.45) | 1.30 (0.8-1.65) | 0.3 (0.2-0.6) | - | <0.001\* |
| Treatment Regimen; n (%) #  ABC/3TC/DRVr  ABC/3TC/DTG  ABC/3TC/EFV  ABC/3TC/NVP  ABC/3TC/RPV  DRV/COB/DTG  RAL/3TC/EFV  TDF/FTC/RPV  TAF/FTC/DTG  TAF/FTC/EFV | 1 (5.25)  3 (15.8)  2 (10.5)  2 (10.5)  3 (15.8)  1 (5.25)  1 (5.25)  3 (15.8)  2 (10.5)  1 (5.25) | - | - | - | - |

\*Kruskal-Wallis, \*\*Chi square test, #At sampling